Table 1. Overall clinical information of GEPNEC and comparative LNEC cohort.
| Characteristics | n (%) | P | |
| GEPNEC
(N=99) |
LNEC
(N=57) |
||
| GEPNEC, gastroenteropancreatic neuroendocrine carcinoma; LNEC, lung NEC; SCNEC, small-cell NEC; LCNEC, large-cell NEC; MiNEN, mixed neuroendocrine-non-neuroendocrine neoplasia; NSE, neuron-specific enolase. #, one NEC patient had difficulty in identifying the small or large cell subtypes; *, we calculated the Ki67 index of NEC component in MiNEN. In most cases (n=12), the Ki67 index of adenocarcinoma component were concordant with that of NEC component. Only 2 MiNEN cases had different Ki67 (median Ki67 for adenocarcinoma was 20% and for NEC was 80%). | |||
Age (year) (
)
|
59.6±12.2 | 61.9±9.8 | 0.054 |
| Gender | |||
| Female | 36 (36.4) | 19 (33.3) | 0.658 |
| Male | 63 (63.6) | 38 (66.7) | |
| Primary sites | − | ||
| Bile duct | 8 (8.1) | − | |
| Colorectum | 18 (18.2) | − | |
| Duodenum | 9 (9.1) | − | |
| Esophagus | 7 (7.1) | − | |
| Stomach | 32 (32.3) | − | |
| Pancreas | 12 (12.1) | − | |
| Unknown primary | 13 (13.1) | − | |
| Lung | − | 57 (100) | − |
| Pathology # | |||
| Undistinguishable | 1 (1.0) | 1 (1.8) | <0.001 |
| LCNEC | 43 (43.4) | 18 (31.6) | |
| SCNEC | 55 (55.6) | 38 (66.7) | |
| Ki67 (%) [Median (IQR)] | 75 (60, 80)* | 80 (70, 90) | 0.072 |
| Mixed component | |||
| MiNEN | 17 (17.2) | 3 (5.3) | 0.032 |
| Pure NEC | 82 (82.8) | 54 (94.7) | |
| Stage | |||
| Stage I−III | 18 (18.2) | 13 (22.8) | 0.234 |
| Stage IV | 81 (81.8) | 44 (77.2) | |
| Metastases | |||
| Liver | 58 (58.6) | 17 (29.8) | 0.061 |
| Lung | 12 (12.1) | − | 0.343 |
| Bone | 9 (9.1) | 9 (15.8) | 0.725 |
| NSE elevation | |||
| No | 34 (34.3) | 17 (29.8) | 0.562 |
| Yes | 65 (65.7) | 40 (70.2) | |
| Smoking | |||
| No | 79 (79.8) | 14 (24.6) | <0.001 |
| Yes | 20 (20.2) | 43 (75.4) | |